ImmunityBio, Inc. (IBRX)
- Previous Close
2.8000 - Open
2.8900 - Bid 2.1900 x 200
- Ask 3.5800 x 200
- Day's Range
2.7800 - 3.0500 - 52 Week Range
1.8300 - 7.6300 - Volume
5,413,714 - Avg. Volume
7,666,847 - Market Cap (intraday)
2.625B - Beta (5Y Monthly) -0.10
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5700 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.40
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
immunitybio.comRecent News: IBRX
View More
Performance Overview: IBRX
Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IBRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IBRX
View MoreValuation Measures
Market Cap
2.47B
Enterprise Value
2.94B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
66.86
Price/Book (mrq)
--
Enterprise Value/Revenue
94.04
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-55.62%
Return on Equity (ttm)
--
Revenue (ttm)
31.22M
Net Income Avi to Common (ttm)
-409.1M
Diluted EPS (ttm)
-0.5700
Balance Sheet and Cash Flow
Total Cash (mrq)
61.59M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-251.77M